Javascript must be enabled to use this form.

View Profile	Home Browse Faculty Facility Research Consortia Training Grants Courses Search Support About rSp Help and FAQ's Contact Us	GCC Home
Faculty Profile Last Modified Time: 08:30:31 AM Tue, 24 Jul 2018   Contact Information Herbert DuPont Associated Profiles  President and CEO, Kelsey Research Foundation, Director, Center for Infectious Diseases, Mary W. Kelsey Chair, Medical Sciences, Professor, Epidemiology, Human Genetics and Environmental Sciences, Internal Medicine, UT Health Science Center at Houston   Reuel A. Stallones Building, Room No.: E743    herbert.l.dupont@uth.tmc.edu     713.500.9366    Web Link    Diarrhea, Mexico, Rifaximin, Enterotoxigenic Escherichia Coli, Escherichia Coli, Clostridium Difficile, Clostridium Infections, Bacillary Dysentery    Associated Profiles Professional Preparation Research and Expertise Affiliations Appointments  Professional Preparation  Degree Major Institution Year  MD Medicine Emory School of Medicine 1965  Research and Expertise Research Interests   Dr. DuPont's major research goals are to define the epidemiology, immunology, genetic resistance, clinical features, control, prevention and therapy of enteric infectious diseases. Laboratory techniques and procedures are typically developed in Houston and taken to the field in an international setting. Four lines of research are currently being conducted by Dr. DuPont and his colleagues. The first is a study of the pathogenesis and epidemiology of diarrhea caused by definable enteric pathogens including enterotoxigenic Escherichia coli (ETEC), enteroaggregative E. coli and norovirus. Molecular typing for epidemiologic studies and novel detection methods including Real-time PCR laboratory methods are being performed in Houston to define microbial virulence genes. Secondly, this group is looking at the host genetics and susceptibility to travelers' diarrhea and post- infectious irritable bowel syndrome (PI-IBS) with a focus on inflammatory cytokine polymorphisms. Thirdly, clinical trials with novel compounds to prevent and treat travelers' diarrhea are being carried out. Currently, the group is evaluating a nonabsorbed rifamycin derivative, rifaximin in the prevention and treatment of acute bacterial diarrhea. Finally, this group is working with new vaccines to prevent bacterial and viral diarrhea. The group just completed an international field trial demonstrating a high degree of effectiveness in preventing travelers' diarrhea and ETEC diarrhea through administration of a transcutaneously applied patch ETEC vaccine developed by IOMAI Corporation. Future clinical studies of safety, immunogenicity and efficacy with this patch vaccine are being planned.  Publications/Creative Works Click here to search for this faculty member's publications on PubMed.  Affiliations  Research Consortia GCC Consortium for Antimicrobial Resistance (GCC AMR)  Appointments Title Department / School Institution Director Center for Infectious and Inflammatory Diseases UT Health Science Center Houston

powering - The Partnership
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.